Internet Pioneer In...
Health Care: Drugs
Amgen Inc (AMGN: NASDAQ)
$67.75 -1.77 | -2.55%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 15.70 | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | 27.30 | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | 10.00 | n.a. | 12.50 |
| Beta | 0.44 | 0.58 | 0.98 |
| Price to Sales (TTM) | 3.31 | 4.62 | 1.42 |
| Price to Book (MRQ) | 2.79 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 15.93 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | 11.00 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | 22.00 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 2.10 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 21.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 9.20 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 3.50 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 1.14 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | 5.20 | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | 5.20 | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | 3.04 | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -22.42 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 2.70 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 3.20 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 1.01 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 1.13 | 0.45 | 0.96 |
| Interest Coverage (TTM) | 6.90 | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 88.80 | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 89.80 | 83.50 | 47.70 |
| EBITD Margin (TTM) | 40.30 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | 43.90 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 26.40 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | 31.80 | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.24 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | 27.00 | 5.30 | 7.00 |
| Return on Assets (TTM) | 7.60 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | 10.00 | 2.20 | 2.50 |
| Return on Investment (TTM) | 9.90 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | 12.30 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 909,943.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | 213,829.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 5.80 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | 0.80 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.30 | 0.40 | 0.40 |
Portfolios with AMGN
- Portfolio NameUser Type
- UserLong Term Stock Picks by Co...
- Contributor5 Low Volatility Low PEG St...
- UserJimboPhi
- UserCorporate Communication cla...
- UserKAREL VON ZOETE
- UserMACHINE RECOMMENDATIONS
- UserMARIA DEL HUERTO
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Health Care Stocks to Watch
- ContributorMost-Searched Stocks for th...
Latest AMGN Headlines from TheStreet
- Symmetry Projections
05.21.12 | 08:05 am - Amgen Inc (AMGN): Today's Featured Drugs Loser 05.18.12 | 05:05 pm
- 5 Cheap, Low-Risk Stocks to Buy 05.18.12 | 07:05 am
- Amgen Stock To Go Ex-dividend Monday (AMGN) 05.11.12 | 08:05 am
- Ex-Dividend Stocks: Target, ConEd 05.11.12 | 07:05 am
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.10.12 | 05:05 pm
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.02.12 | 04:05 pm
- Amgen Reaches New 52-Week High (AMGN) 04.25.12 | 01:04 pm
- Amgen Goes to Turkey, Loses Biotech Cred 04.25.12 | 09:04 am
- Amgen's CEO Discusses Q1 2012 Results - Earnings Call Transcript 04.24.12 | 10:04 pm
Press Releases for AMGN
- Amgen Announces Voting Results Of Annual Meeting Of Stockholders - PR Newswire 05.23.12 | 05:05 pm
- Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia - PR Newswire 05.16.12 | 06:05 pm
- Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - PR Newswire 05.16.12 | 06:05 pm
- Amgen To Present At The Baird Growth Stock Conference - PR Newswire 05.04.12 | 04:05 pm
- Amgen To Present At The Deutsche Bank 37th Annual Healthcare Conference - PR Newswire 05.03.12 | 06:05 pm
- Amgen Receives Complete Response Letter From FDA For XGEVA® SBLA For Prevention Of Bone Metastases - PR Newswire 04.26.12 | 10:04 pm
- Amgen To Acquire Mustafa Nevzat, A Leading Privately Held Turkish Pharmaceutical Company - PR Newswire 04.25.12 | 02:04 am
- A Tribute To George Rathmann, Amgen's Founding CEO (1927-2012) - PR Newswire 04.23.12 | 10:04 pm
- Amgen To Acquire Privately Held KAI Pharmaceuticals - PR Newswire 04.10.12 | 08:04 am
- UCB And Amgen Initiate Sclerostin Antibody Phase 3 Program In Patients With Postmenopausal Osteoporosis - PR Newswire 04.04.12 | 01:04 am
Partner Headlines for AMGN
- Health Care SPDR In Focus Ahead Of Obamacare Decision - Benzinga 05.22.12 | 12:05 pm
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Top Undervalued High Conviction Outperforming Picks From Eaton Vance's $47 Billion Q1 Filng - Seeking Alpha 04.20.12 | 10:04 pm
- Earnings Preview: Abbott Labs - Analyst Blog - Zacks 04.17.12 | 10:04 am
- The Zacks Analyst Blog Highlights: The Goldman Sachs Group, Lloyd's, Bank of America, JPMorgan Chase and Amgen - Press Releases - Zacks 04.12.12 | 09:04 am
- Market Roundup - Benzinga 04.10.12 | 01:04 pm
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Amgen, Abbott, Teva All Incredibly Undervalued Stocks - Seeking Alpha 04.06.12 | 07:04 am
